Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1285155

registered interest
date	09/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to monitor the effectiveness of different covid-19 vaccines on different age groups.
tabling member constituency	Rother Valley
tabling member printed	Alexander Stafford
uin	151889
answer	answer is ministerial correction date of answer 19/02/2021 answer text <p>Public Health England is leading on the surveillance of the COVID-19 vaccine programme and has developed a surveillance strategy to monitor the effectiveness of COVID-19 vaccines against mortality, hospitalisations, confirmed infections, markers of infectiousness and the impact on transmission.</p><p> </p><p>Whilst phase three clinical trials provided evidence of vaccine effectiveness against symptomatic disease, further evidence is needed on how effectiveness varies by subgroup, including by age. This will be done using advanced surveillance techniques once the earliest eligible cohorts have been offered a full course of vaccination.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 151688 151745 151855 question first answered 19/02/2021 10:40:36 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4866 label Biography information for Alexander Stafford

1285207

registered interest
date	09/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to monitor the effectiveness of different covid-19 vaccines on different age groups.
tabling member constituency	Ellesmere Port and Neston
tabling member printed	Justin Madders
uin	151745
answer	answer is ministerial correction date of answer 19/02/2021 answer text <p>Public Health England is leading on the surveillance of the COVID-19 vaccine programme and has developed a surveillance strategy to monitor the effectiveness of COVID-19 vaccines against mortality, hospitalisations, confirmed infections, markers of infectiousness and the impact on transmission.</p><p> </p><p>Whilst phase three clinical trials provided evidence of vaccine effectiveness against symptomatic disease, further evidence is needed on how effectiveness varies by subgroup, including by age. This will be done using advanced surveillance techniques once the earliest eligible cohorts have been offered a full course of vaccination.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 151688 151855 151889 question first answered 19/02/2021 10:40:36 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4418 label Biography information for Justin Madders

1285211

registered interest
date	09/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to monitor the effectiveness of different covid-19 vaccines on different age groups.
tabling member constituency	Ashfield
tabling member printed	Lee Anderson
uin	151855
answer	answer is ministerial correction date of answer 19/02/2021 answer text <p>Public Health England is leading on the surveillance of the COVID-19 vaccine programme and has developed a surveillance strategy to monitor the effectiveness of COVID-19 vaccines against mortality, hospitalisations, confirmed infections, markers of infectiousness and the impact on transmission.</p><p> </p><p>Whilst phase three clinical trials provided evidence of vaccine effectiveness against symptomatic disease, further evidence is needed on how effectiveness varies by subgroup, including by age. This will be done using advanced surveillance techniques once the earliest eligible cohorts have been offered a full course of vaccination.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 151688 151745 151889 question first answered 19/02/2021 10:40:36 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4743 label Biography information for Lee Anderson

1285238

registered interest
date	09/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to UK Covid-19 Vaccines Delivery Plan published on 11 January 2021, what the timetable is for the use of the mobile model to deliver the covid-19 vaccine to people experiencing homelessness.
tabling member constituency	Lancaster and Fleetwood
tabling member printed	Cat Smith
uin	151756
answer	answer is ministerial correction date of answer 17/02/2021 answer text <p>The Government is following the independent advice of the Joint Committee on Vaccination and Immunisation (JCVI), which agrees priority groupings for vaccine. Anyone who is homeless and falls into these groups is eligible for the vaccine and we are working closely with partners to ensure they can access it. NHS England and NHS Improvement are working with voluntary community and social enterprise partners, inclusion health providers and others to develop an accessible model for delivery of the vaccine to people from inclusion health populations. As a result of having two vaccines now deployable, we are considering a number of options and will co-design these with partners based on the different local and logistical considerations.</p><p> </p><p>In the immediate period we are asking partners to support their clients and service users to register with a general practice, where they are not already and if they have health conditions that would make them clinically vulnerable/clinically extremely vulnerable that this is recorded to ensure they receive the vaccine in line with the JCVI’s advice on prioritisation. Over the coming weeks we will consider a range of possible delivery models, including mobile models, to ensure all those prioritised in accordance with the JCVI’s advice receive the vaccine at the appropriate time regardless of their circumstance.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 17/02/2021 16:39:52 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4436 label Biography information for Cat Smith

1285358

registered interest
date	09/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to monitor the effectiveness of different covid-19 vaccines in different age groups.
tabling member constituency	Hendon
tabling member printed	Dr Matthew Offord
uin	151688
answer	answer is ministerial correction date of answer 19/02/2021 answer text <p>Public Health England is leading on the surveillance of the COVID-19 vaccine programme and has developed a surveillance strategy to monitor the effectiveness of COVID-19 vaccines against mortality, hospitalisations, confirmed infections, markers of infectiousness and the impact on transmission.</p><p> </p><p>Whilst phase three clinical trials provided evidence of vaccine effectiveness against symptomatic disease, further evidence is needed on how effectiveness varies by subgroup, including by age. This will be done using advanced surveillance techniques once the earliest eligible cohorts have been offered a full course of vaccination.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 151745 151855 151889 question first answered 19/02/2021 10:40:36 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4006 label Biography information for Dr Matthew Offord

1284773

registered interest
date	08/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when he plans to publish the (a) scientific evidence and (b) his rationale for his Department's policy to extend the gap between covid-19 vaccine doses to 12 weeks.
tabling member constituency	Streatham
tabling member printed	Bell Ribeiro-Addy
uin	150943
answer	answer is ministerial correction date of answer 16/02/2021 answer text <p>Estimates of efficacy of the first dose of COVID-19 vaccines and the rationale for the advice from the Joint Committee on Vaccination and Immunisation is available in the statement published on 31 December which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact" target="_blank">https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact</a></p><p>Further supporting data has since been published on the AstraZeneca vaccine, which indicate high vaccine efficacy from the first dose of vaccine and better immune responses from the second dose with an extended schedule of up to 12 weeks. Data indicates protection from the first dose is maintained over a twelve-week period. This information is available at the following link:</p><p><a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268" target="_blank">https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268</a></p><p>The United Kingdom Chief Medical Officers wrote to the medical profession regarding the COVID-19 vaccination programmes, stating that setting out a model where vaccinating twice the number of people in the next two to three months provides greater public health protection. The letter is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/letter-to-the-profession-from-the-uk-chief-medical-officers-on-the-uk-covid-19-vaccination-programmes/letter-to-the-profession-from-the-uk-chief-medical-officers-regarding-the-uk-covid-19-vaccination-programmes" target="_blank">https://www.gov.uk/government/publications/letter-to-the-profession-from-the-uk-chief-medical-officers-on-the-uk-covid-19-vaccination-programmes/letter-to-the-profession-from-the-uk-chief-medical-officers-regarding-the-uk-covid-19-vaccination-programmes</a></p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 16/02/2021 17:10:13 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4764 label Biography information for Bell Ribeiro-Addy

1284940

registered interest
date	08/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if the Government will publish information on the effectiveness of each type of covid-19 vaccine on (a) immuno-suppressed and (b) other clinically vulnerable people to encourage people in those groups to take up those vaccines.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	150728
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>Public Health England is monitoring the effectiveness and impact of COVID-19 vaccines on a broad range of outcomes including symptomatic disease, infection and hospitalisations as set out in the COVID-19 vaccine surveillance strategy which is available at the following link:</p><p> </p><p><a href="https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Fpublications%2Fcovid-19-vaccine-surveillance-strategy&amp;data=04%7C01%7CParliamentary%40phe.gov.uk%7C7dc5b2e7dcf841c208ab08d8cd22be7f%7Cee4e14994a354b2ead475f3cf9de8666%7C0%7C0%7C637484896395869602%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&amp;sdata=xF%2FF1XBj1dSfVyLXyeuSYASX7Ct%2B5dZ5LtB8jRtg4%2FY%3D&amp;reserved=0" target="_blank">https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-strategy</a></p><p> </p><p>Vaccine effectiveness assessments are reported regularly to the Joint Committee on Vaccination and Immunisation (JCVI) to inform vaccine policy recommendations. This will include assessment of vaccine effectiveness in immunocompromised individuals and the clinically vulnerable using general practice electronic health record data. Vaccine effectiveness data will be published in due course.</p><p> </p><p>Once sufficient evidence becomes available, the JCVI will consider options for a protection strategy for immunosuppressed individuals, including whether any specific vaccine is preferred in this population.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/02/2021 17:20:46 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 82342 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1538 label Biography information for Rosie Cooper

1284942

registered interest
date	08/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what comparative assessment he has made of the implications for safety of NHS trusts waiting (a) 12 and (b) three weeks to give the second dose of the Pfizer vaccine to frontline staff who are caring for covid-19 patients.
tabling member constituency	Sefton Central
tabling member printed	Bill Esterson
uin	150783
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>There is insufficient data to undertake a formal comparative assessment of the implications for safety of different dose intervals with the Pfizer-BioNTech vaccine.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/02/2021 17:34:50 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 82341 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4061 label Biography information for Bill Esterson

1284395

registered interest
date	05/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	TRIPS Agreement
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has undertaken an impact assessment on public health implications for the UK in the event that the proposed World Trade Organisation TRIPS Waiver is not approved.
tabling member constituency	Norwich South
tabling member printed	Clive Lewis
uin	149799
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>The Government has made no such assessment and does not consider waiving intellectual property rights to be an appropriate course of action to boost the manufacturing of safe, effective and quality vaccines. The existing intellectual property framework has mobilised research and development to deliver a host of new medicines and technologies, to detect, treat and defend against COVID-19.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/02/2021 17:26:12 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4500 label Biography information for Clive Lewis

1284130

registered interest
date	04/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he is taking steps to asses the effect of delaying the second Pfizer/Biontech vaccine dose on immunity levels in elderly people against the South African variant of covid-19.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	149182
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>Industry led studies are ongoing to understand the level of protection the Pfizer and AstraZeneca vaccines will provide against variant strains of COVID-19. This will include immunological studies to understand the potential for protection from COVID-19 vaccines against variants and follow up of phase three trial participants in geographical areas where variants are circulating. Global surveillance systems, including systems within Public Health England, will be able to provide observational data on vaccine effectiveness against COVID-19 variants. These will be reviewed by the Joint Committee on Vaccination and Immunisation as they become available.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 149183 question first answered 15/02/2021 17:28:26 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 81562 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1538 label Biography information for Rosie Cooper